LL-37 Therapy

LL-37 disrupts microbial membranes through direct electrostatic interaction with the negatively charged phospholipid bilayers of bacteria, fungi, and enveloped viruses, creating pores that lead to microbial cell death. Beyond direct antimicrobial activity, LL-37 functions as a potent immunomodulator by recruiting immune cells to sites of infection through chemokactic signaling, stimulating cytokine production, and promoting the formation of neutrophil extracellular traps (NETs). It also promotes wound healing by stimulating keratinocyte migration, angiogenesis, and re-epithelialization. LL-37 additionally modulates the adaptive immune response by influencing dendritic cell maturation and T-cell polarization, bridging innate and adaptive immunity.

LL-37 is sought by patients dealing with recurrent or chronic infections, particularly those involving biofilm formation, which are notoriously difficult to address with conventional antimicrobials alone. Individuals with compromised innate immunity or those recovering from significant infections seek LL-37 for additional immune support. It is also popular among patients with chronic Lyme disease concerns and those seeking comprehensive immune defense optimization.

LL-37 is administered via subcutaneous injection, typically near the site of concern when addressing localized infections or systemically for broader immune support. Some practitioners also offer topical formulations for skin applications. Protocols typically involve several weeks of daily or alternate-day injections, with the duration determined by the clinical response and the nature of the immune challenge.